← Leaderboards
Cirle Alcantara Warren
University Of Virginia
$5,314,722
Attributed
$5,521,430
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2014–24$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,521,430 · 6
By mechanism
R01$3,987,233 · 1
R21$1,053,317 · 3
R34$480,880 · 2
Top collaborators
- Nathan Swami2 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Adam N. Goldfarb$16,754,744
- Paul Stokes Hoffman$6,161,174
- Nathan Swami$206,709
Others in their field
Top investigators on “Antibiotics”
- Laurence H Baker · University Of Michigan At Ann Arbor$52,071,546
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,812,829
- Taha E Taha · Johns Hopkins University$37,363,329
- Urs Ochsner · Crestone, Inc.$36,950,837
- Deborah T Hung · Massachusetts General Hospital$36,871,538
- Ryan Cirz · Revagenix, Inc.$35,410,554
Research focus
AntibioticsInfectionClostridium DifficileMouse ModelRecurrenceIn VivoDiarrheaTissuesRelapseIntestinesAntibiotic TherapyToxinCellsIn VitroClinical TrialsSafetyProductionApoptosisMortalityCell LineIncidenceInnovationMediatingResearch Personnel
Grant awards (12)
Alanyl-glutamine supplementation of standard treatment for C. difficile infection$780,536
R01 · FY2024 · AI · contact PI
Alanyl-glutamine supplementation of standard treatment for C. difficile infection$795,802
R01 · FY2023 · AI · contact PI
Alanyl-glutamine supplementation of standard treatment for C. difficile infection$805,350
R01 · FY2022 · AI · contact PI
Disulfiram for Entameoba histolytica Enteric Diarrhea [DEED] Trial$243,880
R34 · FY2022 · AI · contact PI
Alanyl-glutamine supplementation of standard treatment for C. difficile infection$803,224
R01 · FY2021 · AI · contact PI
Alanyl-glutamine supplementation of standard treatment for C. difficile infection$802,321
R01 · FY2020 · AI · contact PI
Optimizing Inter-Microbial Antagonisms to Control Clostridium Difficile Infection$186,702
R21 · FY2018 · AI
Optimizing Inter-Microbial Antagonisms to Control Clostridium Difficile Infection$226,715
R21 · FY2017 · AI
Adenosine receptor-mediated effects of Clostridium difficile toxins in humans$197,500
R21 · FY2017 · AI · contact PI
Adenosine receptor-mediated effects of Clostridium difficile toxins in humans$237,000
R21 · FY2016 · AI · contact PI
PFOR inhibitor amixicile for treatment of drug resistant parasites and bacteria$205,400
R21 · FY2015 · AI · contact PI
Effects of alanyl-glutamine supplementation on C. difficile associated diarrhea$237,000
R34 · FY2014 · AI · contact PI